Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.38 |
| ▸ | MAOB | P27338 | 9/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624062 | 0.85 | KDM4E (0.49) | HRH3SMN1; SMN2CYP3A4 | |
| SCHEMBL13930950 | 0.79 | LTA4H (0.50) | HRH3MAOBCYP3A4 | |
| SCHEMBL13930953 | 0.76 | HRH3 (0.42) | HRH3MAOBSMN1; SMN2CYP3A4 | |
| SCHEMBL13930848 | 0.76 | HRH3 (0.43) | HRH3MAOBSMN1; SMN2CYP3A4 | |
| SCHEMBL13461863 | 0.75 | DRD2 (0.48) | — | |
| SCHEMBL13930782 | 0.75 | NQO1 (0.61) | SMN1; SMN2 | |
| SCHEMBL12585293 | 0.73 | KCNA3 (0.54) | — | |
| SCHEMBL14934602 | 0.72 | HRH3 (0.52) | HRH3MAOB | |
| SCHEMBL13930961 | 0.72 | NFE2L2 (0.60) | HRH3MAOB | |
| SCHEMBL27813753 | 0.70 | KDM4E (0.32) | HRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | HRH3 2874/4885MAOB 3220/4885SMN1; SMN2 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.